Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3

被引：7

作者：

Nichols, G. ^{[1
]}

Mills, A. ^{[2
]}

Grossberg, R. ^{[3
]}

Lazzarin, A. ^{[4
]}

Maggiolo, F. ^{[5
]}

Molina, J. ^{[6
]}

Pialoux, G. ^{[7
]}

Wright, D. ^{[8
]}

Ait-Khaled, M. ^{[9
]}

Huang, J. ^{[10
]}

Vavro, C. ^{[1
]}

Wynne, B. ^{[11
]}

Yeo, J. ^{[9
]}

机构：

[1] GlaxoSmithKline, Res Triangle Pk, NC USA

[2] Anthony Mills MD Inc, Los Angeles, CA USA

[3] Montefiore Med Ctr, New York, NY USA

[4] Ist Sci San Raffaele, I-20132 Milan, Italy

[5] Osped Riuniti Bergamo, I-24100 Bergamo, Italy

[6] Hosp St Louis, Paris, France

[7] Hosp Tenon, Paris, France

[8] Cent Texas Clin Res, Austin, TX USA

[9] GlaxoSmithKline, London, England

[10] GlaxoSmithKline, Mississauga, ON, Canada

[11] GlaxoSmithKline, Philadelphia, PA USA

来源：

JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2012年 / 15卷

关键词：

D O I：

10.7448/IAS.15.6.18112

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：8 / 8

页数：1

共 50 条

[1] Evolution of integrase in virus at protocol-defined virological failure from the VIKING-3 study
Vavro, C. L.
Huang, J.
Ait-Khaled, M.
Yeo, J. M.
ANTIVIRAL THERAPY, 2013, 18 : A104 - A104
[2] Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
Castagna, Antonella
Maggiolo, Franco
Penco, Giovanni
Wright, David
Mills, Anthony
Grossberg, Robert
Molina, Jean-Michel
Chas, Julie
Durant, Jacques
Moreno, Santiago
Doroana, Manuela
Ait-Khaled, Mounir
Huang, Jenny
Min, Sherene
Song, Ivy
Vavro, Cindy
Nichols, Garrett
Yeo, Jane M.
JOURNAL OF INFECTIOUS DISEASES, 2014, 210 (03): : 354 - 362
[3] An analysis of minor variants in HIV-1 integrase (IN) for subjects with only historic evidence of integrase inhibitor (INI) resistance enrolled in study ING112574 (VIKING-3)
Paredes, R.
Noguera-Julian, M.
Pou, C.
Horton, J.
Remlinger, K.
Vavro, C.
ANTIVIRAL THERAPY, 2014, 19 : A43 - A43
[4] Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study
Akil, Bisher
Blick, Gary
Hagins, Debbie P.
Ramgopal, Moti N.
Richmond, Gary J.
Samuel, Rafik M.
Givens, Naomi
Vavro, Cindy
Song, Ivy H.
Wynne, Brian
Ait-Khaled, Mounir
ANTIVIRAL THERAPY, 2015, 20 (03) : 343 - 348
[5] Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice
Alteri, Claudia
Scutari, Rossana
Bertoli, Ada
Armenia, Daniele
Gori, Caterina
Fabbri, Gabriele
Mastroianni, Claudio Maria
Cerva, Carlotta
Cristaudo, Antonio
Vicenti, Ilaria
Bruzzone, Bianca
Zazzi, Maurizio
Andreoni, Massimo
Antinori, Andrea
Svicher, Valentina
Ceccherini-Silberstein, Francesca
Perno, Carlo Federico
Santoro, Maria Mercedes
VIRUS GENES, 2019, 55 (03) : 290 - 297
[6] Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice
Claudia Alteri
Rossana Scutari
Ada Bertoli
Daniele Armenia
Caterina Gori
Gabriele Fabbri
Claudio Maria Mastroianni
Carlotta Cerva
Antonio Cristaudo
Ilaria Vicenti
Bianca Bruzzone
Maurizio Zazzi
Massimo Andreoni
Andrea Antinori
Valentina Svicher
Francesca Ceccherini-Silberstein
Carlo Federico Perno
Maria Mercedes Santoro
Virus Genes, 2019, 55 : 290 - 297
[7] Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥ 50 Years: Final 96-Week Results of the NEAT022 Study
Gatell, Jose M.
Assoumou, Lambert
Moyle, Graeme
Waters, Laura
Johnson, Margaret
Domingo, Pere
Fox, Julie
Martinez, Esteban
Stellbrink, Hans-Juergen
Guaraldi, Giovanni
Masia, Mar
Gompels, Mark
De Wit, Stephane
Florence, Eric
Esser, Stefan
Raffi, Francois
Stephan, Christoph
Rockstroh, Juergen
Giacomelli, Andrea
Vera, Jaime
Ignacio Bernardino, Jose
Winston, Alan
Saumoy, Maria
Gras, Julien
Katlama, Christine
Pozniak, Anton L.
Vandekerckhove, Linos
Caluwe, Els
De Wit, Stephane
Necsoi, Coca
Florence, Eric
Van Frankenhuijsen, Maartje
Raffi, Francois
Allavena, Clotilde
Reliquet, Veronique
Cavellec, Morane
Rodallec, Audrey
Le Tourneau, Thierry
Connault, Jerome
Molina, Jean-Michel
Ferret, Samuel
Previlon, Miresta
Yazdanpanah, Yazdan
Landman, Roland
Joly, Veronique
Martinez, Adriana Pinto
Katlama, Christine
Caby, Fabienne
Ktorza, Nadine
Schneider, Luminita
CLINICAL INFECTIOUS DISEASES, 2019, 68 (04) : 597 - 606
[8] Safety Results From Dual PDE3/4 Inhibitor Ensifentrine: Gastrointestinal and Cardiovascular Safety From a 24-week Phase 3 Trial, Enhance-2
Siler, T. M.
Rickard, K.
Bengtsson, T.
Rheault, T.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[9] Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254+dolutegravir as a 2-drug regimen in treatment-naive adults: 24-week results from the Phase IIb DYNAMIC study
Joshi, S. R.
Masia, M.
Mitha, E.
Castagna, A.
Cordova, E.
Ramgopal, M.
Gaudion, A.
Karthika, S.
Oyee, J.
Bainbridge, V.
Wynne, B.
Lataillade, M.
HIV MEDICINE, 2023, 24 : 210 - 211
[10] An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1
Evitt, Lee A. A.
Nanji, Sakina
Grove, Richard A. A.
Okoli, Chinyere
van Wyk, Jean
Snedecor, Sonya J. J.
AIDS RESEARCH AND THERAPY, 2023, 20 (01)

← 1 2 3 4 5 →